Clinical and patient-reported outcomes based on achieved hemoglobin levels in chemotherapy-treated cancer patients receiving erythropoiesis-stimulating agents

Community Oncology

Volumn 6, Issue 9, 2009, Pages 403-408

  Larholt, Kay ^a   Burton, Tanya M ^a   Hoaglin, David C ^a   Pashos, Chris L ^a   Bookhart, Brahim K ^b   Corral, Mitra ^b   Piech, Catherine Tak ^b   McKenzie, R Scott ^b  

^a Abt Bio Pharma Solutions Inc   (United States)

^b Centocor Ortho Biotech Services LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; DRUG INDUCED DISEASE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEALTH CARE POLICY; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; REIMBURSEMENT; SELF REPORT; TREATMENT OUTCOME;

EID: 70350448836     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70269-8     Document Type: Article

References (30)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
2. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-2221. (Pubitemid 32552805)
3. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25(3 suppl 7):43-46. (Pubitemid 28326224)
4. Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001;28(2 suppl 8):15-18. (Pubitemid 32522232)
5. Procrit (epoetin alfa) Full Prescribing Information. Raritan, NJ: Ortho Biotech Products, L.P. (distributor), revised August 2008.
6. Aranesp (darbepoetin alfa) Full Prescribing Information. Thousand Oaks, CA: Amgen, Inc., revised August 2008.
7. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25-41.
8. NCCN Clinical Practice Guidelines in Oncology: Cancer- and chemotherapy-induced anemia (V.3.2009). Available at: www.nccn.org. Accessed August 25, 2009.
9. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617. (Pubitemid 46179449)
10. Vansteenkiste J, Tomita D, Rossi G, Pirker R. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer 2004;12:253-262. (Pubitemid 38660748)
11. Centers for Medicare and Medicaid Services (CMS). 110.21 Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions. Pub 100-103 Medicare National Coverage Determinations Manual. Washington, DC: US Department of Health and Human Services; 2008.
12. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972. (Pubitemid 46300213)
13. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-325.
14. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260. (Pubitemid 37324251)
15. Larholt K, Pashos CL, Wang Q, Bookhart B, McKenzie RS, Piech CT. Dosing and Outcomes Study of Erythropoiesis-stimulating Therapies (DOSE): a registry for characterizing anaemia management and outcomes in oncology patients. Clin Drug Investig 2008;28:159-167. (Pubitemid 351239081)
16. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 suppl 2):13-19. (Pubitemid 27319140)
17. Vadhan-Raj S, Mirtsching B, Terry D, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-138.
18. Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006;11:409-417.
19. Gilmore J, Feinberg BA, Gondesen T, Jackson J, Bookhart BK, McKenzie RS. Hematologic and transfusion outcomes following implementation of the Erythropoiesis-Stimulating Agent (ESA) National Coverage Determination (NCD) in Medicare cancer patients receiving chemotherapy. J Clin Oncol 2008;26(15S):6548.
20. Naeim A, Glaspy J. Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007. J Clin Oncol 2008;26(15S):20595.
21. Hess G, Nordyke RJ, Pirolli M, Hulnick S, Curry A, Gesme D. Effect of changes in labeling and reimbursement on use of ESAs and transfusions. J Clin Oncol 2008;26(15S):20589.
22. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A (suppl 2):S2-S8.
23. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874. (Pubitemid 32538196)
24. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. PROCRIT Study Group. J Clin Oncol 1997;15:1218-1234. (Pubitemid 27106310)
25. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425. (Pubitemid 28481641)
26. Charu V, Saidman B, Ben-Jacob A, et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist 2007;12:1253-1263. (Pubitemid 350106356)
27. Pirker R, Ramlau RA, Schuette W, et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342-2349.
28. Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-9386. (Pubitemid 46260197)
29. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008;26:592-598. (Pubitemid 351264353)
30. Moebus V, Lueck H, Thomssen C, et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: mature results of an AGO phase III study (ETC trial). J Clin Oncol 2007;25(18S):569.